The Wolverine Stack After the FDA Votes: Full Status Report
The Wolverine stack — BPC-157 plus TB-500, with GHK-Cu often riding shotgun — is the most-run recovery protocol in the research community. In one July meeting, its entire roster got regulatory news: both core compounds cleared the FDA's compounding committee 8–6, and GHK-Cu got queued for its own review by February 2027. Here is the post-vote state of the stack, minus the hype.
Both Halves Passed. Together.
BPC-157 and TB-500 were voted on the same day, July 23, and passed by identical 8–6 margins with one abstention each. The committee effectively treated the day-one wound-and-tissue trio (KPV included) as a bloc. For stack runners, that symmetry matters: the two compounds' regulatory fates are now moving in parallel, so a future world where one is compoundable and the other is not looks less likely than it did in June.
What the FDA Actually Evaluated
| Compound | Evaluated Use | Stack Role |
|---|---|---|
| BPC-157 | Ulcerative colitis | Tendon/ligament/gut recovery (street use) |
| TB-500 | Wound healing | Connective tissue, cell migration |
| GHK-Cu | Review pending — noninjectable routes, by Feb 2027 | Skin, collagen, wound support |
Note the mismatch on BPC-157: the evaluated indication is gut, not tendon. TB-500 is the one whose evaluated use actually matches how the stack community uses it.
What Changed for Stack Runners
- Legality: nothing. Both compounds remain research-only until rulemaking finishes — 12–24 months minimum if the FDA moves, with the four-years-and-counting glutathione stall as the cautionary precedent.
- Doping status: nothing. BPC-157 and TB-500 are both banned by international anti-doping authorities. Tested athletes were out before the vote and are out after it.
- Quality stakes: raised. FDA staff testified they have found different active molecules sold under the same peptide names. If you run this stack from research suppliers, COA verification is the whole game.
- The 2027 horizon: real. If rulemaking proceeds and GHK-Cu's February review goes well, the entire stack could plausibly have licensed pathways within a few years. That is a first.
The Play
Run your research exactly as carefully as you did in June — same suppliers you have vetted, same third-party testing standards, same honesty about the thin human evidence. The regulatory wind shifted in your favor; it did not blow the gray zone away. We will flag the moment a proposed rule drops.
Compound deep-dives: BPC-157's vote, TB-500's vote, and the science files at PeptideOnline.
Partner links. Research compounds are for laboratory use only.
Questions
Yes. BPC-157 and TB-500 each passed 8-6 with one abstention on July 23, 2026, and GHK-Cu is queued for its own PCAC review by February 2027.
No. Both compounds remain research-only. Rulemaking must finish before any legal compounding - realistically 2027 or later.
No. BPC-157 and TB-500 are both prohibited by anti-doping authorities, and the votes change nothing about testing status.
GHK-Cu has not been reviewed yet - the FDA expects a PCAC consultation on noninjectable routes before the end of February 2027.
Identity. FDA staff reported finding different active molecules sold under identical peptide names, which makes COA and third-party test verification essential.